Early at the beginning of the year, Renishaw teamed up with researchers from Herantis Pharma plc, to help investigate cerebral dopamine neurotrophic factor (CDNF) as a treatment for Parkinson’s disease.
Renishaw contributed in providing a drug delivery system that consists of up to four catheters, that can be implanted into target areas within the brain. The catheters were accessed via a 3D printed titanium transcutaneous port implanted behind the patient’s ear.
Today, the global engineering company announced that its drug delivery system has allowed for repeated, intermittent infusions into the parenchyma. Furthermore, it has continued to safely and effectively deliver infusions as part of this clinical trial.
This clinical drug trial means a lot for the teams involved as it is the first-in-human clinical trial of cerebral dopamine neurotrophic factor (CDNF).
In a press communication, the company explained that initial results from the main study indicated predictable and accurate placement of the device as well as its positive performance and safety. With the 15 patients who progressed into the extension study, device safety was further demonstrated, with no serious adverse events (SAEs) considered to have device or drug causality. Additionally, the unique ability to deliver repeated infusions continued to facilitate the assessment of CDNF’s safety and early efficacy.
Rupert Jones, Managing Director of Renishaw Neuro Solutions Ltd, said, “Now the extension study has reached its completion, I would once again like to extend a huge thankyou to the trial participants for making this study possible, making personal sacrifices that will ultimately benefit fellow and future Parkinson’s Disease patients.”
He continues, “I’m delighted to see Renishaw’s drug delivery system continuing to facilitate repeated infusions over an extended period of time for such a complex condition as Parkinson’s Disease. The device’s performance demonstrates what a powerful delivery platform it is for the treatment of many, currently incurable, neurological conditions, opening new possibilities in the field of neurosurgery and neuroscience. I see this as a hugely positive step forward and believe all involved in the study should be proud of their achievements.”
During the upcoming Additive-Talks Day, Renishaw will take part on a panel discussion entitled : “How to increase process productivity for replacement parts”. Register NOW and take part in a live conversation between Renishaw, Deutsche Bahn and BMT Aerospace.
Remember, you can post AM job opportunities for free on 3D ADEPT Media or look for a job via our job board. Make sure to follow us on our social networks and subscribe to our weekly newsletter: Facebook, Twitter, LinkedIn & Instagram! If you want to be featured in the next issue of our digital magazine or if you hear a story that needs to be heard, make sure to send it to contact@3dadept.com